Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
McKesson
Baxter
Express Scripts

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,226,912

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,226,912
Title:Acetyltanshinone IIA (ATA) as anticancer agent
Abstract: The present invention relates to the use of a compound of Formula I for the manufacture of a medicament for treating or preventing cancer in a subject. Formula I ##STR00001##
Inventor(s): Luo; Kathy Qian (Singapore, SG), Yu; Ting (Singapore, SG), Luo; Hou-Wei (Singapore, SG)
Assignee: Nanyang Technological University (Singapore, SG)
Application Number:14/009,431
Patent Claims:1. A method for inhibiting estrogen receptor signaling in a cell, comprising contacting said cell with an effective amount of a compound of Formula I ##STR00006##

2. The method of claim 1, wherein estrogen receptor signaling is inhibited by estrogen receptor protein degradation, reduced estrogen receptor mRNA levels and/or inhibition of estrogen receptor-responsive gene expression.

3. The method of claim 1, wherein HER2 expression is reduced in the cell after contacting said cell with an effective amount of a compound of Formula I ##STR00007##

4. The method of claim 3, wherein the cell is an estrogen receptor positive/HER2 positive (ER+/HER2+) breast cancer cell.

5. A method for inducing apoptosis in a cell, comprising contacting said cell with an effective amount of a compound of Formula I ##STR00008##

6. The method of claim 5, wherein apoptosis is induced by generation of reactive oxygen species.

7. A method for treating cancer selected from breast cancer, cervical cancer, lung cancer, liver cancer, colorectal adenocarcinoma, neuroblastoma, melanoma, and leukemia in a subject, comprising administering an effective amount of a compound of Formula I to a subject in need thereof ##STR00009##

8. The method of claim 7, wherein the cancer is estrogen receptor-positive (ER+) breast cancer.

9. The method of claim 7, wherein the cancer is HER2 positive (HER2+) breast cancer.

10. The method of claim 7, wherein the method further comprises administering a second anticancer agent to the subject.

11. The method of claim 10, wherein the second anticancer agent is administered before, together with or after the compound of Formula I.

12. The method of claim 10, wherein the second anticancer agent is selected from the group consisting of paclitaxel, doxorubicin, herceptin, lapatinib, gefitinib, erlotinib, tamoxifen, fulvestrant, anastrazole, lectrozole, exemestane, fadrozole and combinations thereof.

13. The method of claim 7, wherein the subject has prior to administration of the compound of Formula I underwent anticancer therapy with a different anticancer agent or anticancer agent combination.

14. The method of claim 7, wherein the subject has previously been treated with an anticancer agent selected from the group of selective estrogen receptor modulators, estrogen receptor down regulators, aromatase inhibitors, HER2 inhibitors, anthracyclines, and combinations thereof.

15. The method of claim 14, wherein the anticancer agent is selected from the group consisting of doxorubicine, paclitaxel, herceptin, lapatinib, gefitinib, erlotinib, tamoxifen, fulvestrant, anastrazole, lectrozole, exemestane, fadrozole and combinations thereof.

16. The method of claim 13, wherein the subject has failed the previous therapy.

17. The method of claim 13, wherein the subject has developed resistance to one or more of the previously used anticancer agents.

18. The method of claim 7, wherein the subject is a mammal.

19. The method of claim 7, wherein the subject is a human.

Details for Patent 9,226,912

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Sign up for a Free Trial 2031-04-07
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Sign up for a Free Trial 2031-04-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKinsey
Merck
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.